BTK Inhibitors Are The Next Big Race In MS
Executive Summary
BTK inhibitors are in late-stage development for multiple sclerosis, with Merck KgAA and Sanofi in the lead and Roche and Novartis close behind.
Topics
- Subjects
- Clinical Trials
- Business Strategies
- Research & Development
- Therapy Areas
- Immune Disorders
- Industries
- BioPharmaceutical
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC146491
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.
All fields are required.
SC146491
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.